1.2M XNAS Volume
XNAS 19 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Melody Harris | Chf Ops Off, Pres, Informatics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 2,056 | 109,755 (0%) | 0% | 0 | Common Stock | |
| Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 16,886 | - | - | Restricted Stock Unit | |
| Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 84,317 | 84,317 | - | - | Restricted Stock Unit | |
| Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 143,266 | 143,266 | - | - | Stock Option (Right to Buy) | |
| Warren Stone | Chief Commerical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 2,472 | 90,793 (0%) | 0% | 0 | Common Stock | |
| Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 93,265 (0%) | 0% | 0 | Common Stock | |
| Alicia C. Olivo | EVP, GC & Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 16,886 | - | - | Restricted Stock Unit | |
| Alicia C. Olivo | EVP, GC & Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 63,238 | 63,238 | - | - | Restricted Stock Unit | |
| Alicia C. Olivo | EVP, GC & Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 107,450 | 107,450 | - | - | Stock Option (Right to Buy) | |
| Alicia C. Olivo | EVP, GC & Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 2,504 | 45,353 (0%) | 0% | 0 | Common Stock | |
| Alicia C. Olivo | EVP, GC & Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 47,857 (0%) | 0% | 0 | Common Stock | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 111,811 (0%) | 0% | 0 | Common Stock | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 143,266 | 143,266 | - | - | Stock Option (Right to Buy) | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 84,317 | 84,317 | - | - | Restricted Stock Unit | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 16,886 | - | - | Restricted Stock Unit | |
| Gregory D. Aunan | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 18,971 | 18,971 | - | - | Restricted Stock Unit | |
| Gregory D. Aunan | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 31,163 | 31,163 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 15,535 | 141,271 (0%) | 0% | 0 | Common Stock | |
| Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 15,535 | 31,071 | - | - | Restricted Stock Unit | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 126,476 | 126,476 | - | - | Restricted Stock Unit | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 214,900 | 214,900 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 4,207 | 137,064 (0%) | 0% | 0 | Common Stock | |
| Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | |
| Alicia C. Olivo | EVP, GC & Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Jan 2025 | 7,070 | 102,820 (0%) | 0% | 0 | Common Stock | |
| Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 07 Dec 2024 | 11,746 | 123,754 (0%) | 0% | 0 | Common Stock | |
| Warren Stone | Chief Commerical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Dec 2024 | 6,224 | 84,822 (0%) | 0% | 0 | Common Stock | |
| Alicia C. Olivo | General Counsel | Sale of securities on an exchange or to another person at price $ 15.36 per share. | 15 Nov 2024 | 5,175 | 37,129 (0%) | 0% | 15.4 | 79,475 | Common Stock |
| Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Sep 2024 | 1,666 | 42,147 (0%) | 0% | 0 | Common Stock | |
| Alicia C. Olivo | General Counsel | Sale of securities on an exchange or to another person at price $ 16.05 per share. | 15 Aug 2024 | 1,040 | 43,813 (0%) | 0% | 16.1 | 16,695 | Common Stock |
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 61,398 (0%) | 0% | 0 | Common Stock | |
| Anthony P. Zook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Anthony P. Zook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 11,336 (0%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Michael A. Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 31,755 (0%) | 0% | 0 | Common Stock | |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 118,769 (0%) | 0% | 0 | Common Stock | |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Stephen M. Kanovsky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Stephen M. Kanovsky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 36,090 (0%) | 0% | 0 | Common Stock | |
| David B. Perez | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 21,636 (0%) | 0% | 0 | Common Stock | |
| David B. Perez | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Elizabeth A. Floegel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Elizabeth A. Floegel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 11,336 (0%) | 0% | 0 | Common Stock | |
| Neil Gunn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Neil Gunn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 11,336 (0%) | 0% | 0 | Common Stock | |
| Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Aug 2024 | 14 | 44,853 (0%) | 0% | 0 | Common Stock | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Anthony P. Zook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Anthony P. Zook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Stephen M. Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Stephen M. Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| David B. Perez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| David B. Perez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Elizabeth A. Floegel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Elizabeth A. Floegel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Neil Gunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Neil Gunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Alicia C. Olivo | General Counsel | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 15 May 2024 | 1,049 | 44,867 (0%) | 0% | 15.7 | 16,511 | Common Stock |
| Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 3,167 | 135,500 (0%) | 0% | 14.9 | 47,062 | Common Stock |
| Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 138,667 (0%) | 0% | 0 | Common Stock | |
| Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 26,011 | - | - | Restricted Stock Unit | |
| Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 148,505 (0%) | 0% | 0 | Common Stock | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 7,068 | 110,023 (0%) | 0% | 0 | Common Stock | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 1,722 | 108,301 (0%) | 0% | 14.9 | 25,589 | Common Stock |
| Melody Harris | Chf Ops Off, Pres, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 7,068 | 14,136 | - | - | Restricted Stock Unit | |
| Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 13,006 | - | - | Restricted Stock Unit | |
| Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 45,916 (0%) | 0% | 0 | Common Stock | |
| Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 1,584 | 39,414 (0%) | 0% | 14.9 | 23,538 | Common Stock |
| Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 40,998 (0%) | 0% | 0 | Common Stock | |
| Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 9,612 | 19,226 | - | - | Restricted Stock Unit | |
| Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 9,612 | 100,658 (0%) | 0% | 0 | Common Stock | |
| Warren Stone | Chief Commerical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 2,341 | 91,046 (0%) | 0% | 14.9 | 34,787 | Common Stock |
| Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 9,612 | 93,387 (0%) | 0% | 0 | Common Stock | |
| Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 26,011 | - | - | Restricted Stock Unit | |
| Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 138,667 (0%) | 0% | 0 | Common Stock | |
| Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 3,167 | 135,500 (0%) | 0% | 14.9 | 47,062 | Common Stock |
| Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 40,998 (0%) | 0% | 0 | Common Stock | |
| Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 1,584 | 39,414 (0%) | 0% | 14.9 | 23,538 | Common Stock |
| Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 13,006 | - | - | Restricted Stock Unit | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 19,984 | 19,984 | - | - | Stock Option (Right to Buy) | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 11,939 | 11,939 | - | - | Performance Stock Unit | |
| Melody Harris | Chf Ops Off, Pres, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 11,939 | 11,939 | - | - | Restricted Stock Unit | |
| Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 29,976 | 29,976 | - | - | Stock Option (Right to Buy) | |
| Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 17,908 | 17,908 | - | - | Restricted Stock Unit | |
| Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 17,908 | 17,908 | - | - | Performance Stock Unit | |
| Gregory D. Aunan | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 16,117 | 16,117 | - | - | Restricted Stock Unit | |
| Gregory D. Aunan | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 May 2024 | 937 | 14,453 (0%) | 0% | 0 | Common Stock | |
| Gregory D. Aunan | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 26,978 | 26,978 | - | - | Stock Option (Right to Buy) | |
| Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 May 2024 | 652 | 34,496 (0%) | 0% | 0 | Common Stock | |
| Lynn A. Tetrault | Director | Sale of securities on an exchange or to another person at price $ 15.97 per share. | 04 Mar 2024 | 6,112 | 50,062 (0%) | 0% | 16.0 | 97,579 | Common Stock |
| Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,329 | 25,329 | - | - | Restricted Stock Unit | |
| Harris Melody | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,329 | 25,329 | - | - | Restricted Stock Unit | |
| Olivo Alicia C. | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,329 | 25,329 | - | - | Restricted Stock Unit | |
| Stone Warren | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,330 | 25,330 | - | - | Performance Stock Unit | |
| Sikri Vishal | President Advanced Diagnostics | 23 Feb 2024 | 25,329 | 25,329 | - | - | Restricted Stock Unit | ||
| Sikri Vishal | President Advanced Diagnostics | 23 Feb 2024 | 25,330 | 25,330 | - | - | Performance Stock Unit | ||
| Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 42,344 | 42,344 | - | - | Stock Option (Right to Buy) | |
| S. Sherman Jeffrey | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 46,606 | 46,606 | - | - | Performance Stock Unit | |
| Sherman Jeffrey S. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 77,913 | 77,913 | - | - | Stock Option (Right to Buy) | |
| Harris Melody | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 42,344 | 42,344 | - | - | Stock Option (Right to Buy) | |
| Vishal Sikri | President Advanced Diagnostics | 23 Feb 2024 | 42,344 | 42,344 | - | - | Stock Option (Right to Buy) | ||
| Olivo C. Alicia | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,330 | 25,330 | - | - | Performance Stock Unit | |
| C. Alicia Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 42,344 | 42,344 | - | - | Stock Option (Right to Buy) | |
| S. Jeffrey Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 46,606 | 46,606 | - | - | Restricted Stock Unit | |
| Melody Harris | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,330 | 25,330 | - | - | Performance Stock Unit | |
| Alicia Olivo C. | General Counsel | Sale of securities on an exchange or to another person at price $ 14.96 per share. | 15 Feb 2024 | 2,587 | 34,866 (0%) | 0% | 15.0 | 38,713 | Common Stock |
| Harris Melody | President, Enterprise Ops | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Jan 2024 | 7,123 | 102,955 (0%) | 0% | 0 | Common Stock | |
| Jeffrey Sherman S. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 07 Dec 2023 | 8,147 | 125,662 (0%) | 0% | 0 | Common Stock | |
| Stone Warren | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Dec 2023 | 5,431 | 83,775 (0%) | 0% | 0 | Common Stock | |
| Bruce K. Crowther | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Bruce K. Crowther | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Tony Zook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Tony Zook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Stephen Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Stephen Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| David B. Perez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| David B. Perez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Floegel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Elizabeth Floegel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Neil Gunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Neil Gunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Aug 2023 | 14 | 40,981 (0%) | 0% | 0 | Common Stock | |
| Vishal Sikri | President Advanced Diagnostics | 01 Jun 2023 | 21,406 | 127,716 (0%) | 0% | 0 | Common Stock | ||
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.60 per share. | 22 May 2023 | 1,507 | 56,174 (0%) | 0% | 11.6 | 17,481 | Common Stock |
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 1,507 | 0 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 39,016 | 39,016 | - | - | Performance Stock Unit | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 39,016 | 39,016 | - | - | Restricted Stock Unit | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 73,016 | 73,016 | - | - | Stock Option (Right to Buy) | |
| Melody Harris | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 21,204 | 21,204 | - | - | Performance Stock Unit | |
| Melody Harris | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 21,204 | 21,204 | - | - | Restricted Stock Unit | |
| Melody Harris | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 39,683 | 39,683 | - | - | Stock Option (Right to Buy) | |
| Vishal Sikri | President Advanced Diagnostics | 11 May 2023 | 39,683 | 39,683 | - | - | Stock Option (Right to Buy) | ||
| Vishal Sikri | President Advanced Diagnostics | 11 May 2023 | 21,204 | 21,204 | - | - | Restricted Stock Unit | ||
| Vishal Sikri | President Advanced Diagnostics | 11 May 2023 | 21,204 | 21,204 | - | - | Performance Stock Unit | ||
| Alicia C. Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 19,508 | 19,508 | - | - | Performance Stock Unit | |
| Alicia C. Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 19,508 | 19,508 | - | - | Restricted Stock Unit | |
| Alicia C. Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 36,508 | 36,508 | - | - | Stock Option (Right to Buy) | |
| Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 28,838 | 28,838 | - | - | Restricted Stock Unit | |
| Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 53,969 | 53,969 | - | - | Stock Option (Right to Buy) | |
| Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 21,204 | 21,204 | - | - | Performance Stock Unit | |
| Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 May 2023 | 662 | 40,694 (0%) | 0% | 0 | Common Stock | |
| Shashikant Kulkarni | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Apr 2023 | 3,759 | 82,673 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2023 | 117 | 29,765 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2023 | 880 | 29,882 (0%) | 0% | 0 | Common Stock | |
| Melody Harris | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 201,613 | 201,613 | - | - | Stock Option (Right to Buy) | |
| Melody Harris | President, Enterprise Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 108,225 | 108,225 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 31 Dec 2022 | 959 | 30,762 (0%) | 0% | 0 | Common Stock | |
| Vishal Sikri | President, Pharma Services | 31 Dec 2022 | 225 | 148,680 (0%) | 0% | 7.0 | 1,584 | Common Stock | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 89,206 | 133,809 (0%) | 0% | 0 | Common Stock | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 249,169 | 249,169 | - | - | Stock Option (Right to Buy) | |
| Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 44,603 | 44,603 (0%) | 0% | 0 | Common Stock | |
| Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 166,113 | 166,113 | - | - | Stock Option (Right to Buy) | |
| Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 89,206 | 89,206 (0%) | 0% | 0 | Common Stock | |
| David B. Perez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2022 | 9,730 | 9,730 | - | - | Stock Option (Right to Buy) | |
| David B. Perez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2022 | 10,300 | 10,300 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 13,141 | 31,721 (0%) | 0% | 0 | Common Stock | |
| David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 25,826 | 25,826 | - | - | Stock Option (Right to Buy) | |
| David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 12,352 | 43,216 (0%) | 0% | 0 | Common Stock | |
| Shashikant Kulkarni | President of Lab Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 51,653 | 51,653 | - | - | Stock Option (Right to Buy) | |
| Shashikant Kulkarni | President of Lab Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 24,704 | 65,856 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 22 Jun 2022 | 57 | 18,580 (0%) | 0% | 0 | Common Stock | |
| Bruce K. Crowther | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 65,120 (0%) | 0% | 0 | Common Stock | |
| Bruce K. Crowther | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Option (Right to Buy) | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Option (Right to Buy) | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 54,667 (0%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 20,419 (0%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Option (Right to Buy) | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 107,433 (0%) | 0% | 0 | Common Stock | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Option (Right to Buy) | |
| Stephen Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Options (Right to Buy) | |
| Stephen Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 24,754 (0%) | 0% | 0 | Common Stock | |
| Rachel A. Stahler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Option (Right to Buy) | |
| Rachel A. Stahler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 21,335 (0%) | 0% | 0 | Common Stock | |
| Vishal Sikri | President and CCO, Inivata | 01 Jun 2022 | 319,112 | 319,112 | - | - | Stock Option (Right to Buy) | ||
| Vishal Sikri | President and CCO, Inivata | 01 Jun 2022 | 148,455 | 148,455 (0%) | 0% | 0 | Common Stock | ||
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2022 | 3,334 | 0 | - | - | Stock Option (Right to Buy) | |
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 18 May 2022 | 3,334 | 39,111 (0%) | 0% | 7.3 | 24,238 | Common Stock |
| William B. Bonello | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 28 Apr 2022 | 5,727 | 191,548 (0%) | 0% | 7.5 | 43,067 | Common Stock |
| William B. Bonello | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 5,727 | 0 | - | - | Stock Option (Right to Buy) | |
| William B. Bonello | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 82,305 | 185,821 (0%) | 0% | 0 | Common Stock | |
| Douglas M. Brown | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 82,305 | 158,684 (0%) | 0% | 0 | Common Stock | |
| David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 66,372 | 66,372 | - | - | Stock Option (Right to Buy) | |
| David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 30,864 | 30,864 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 07 Mar 2022 | 5,000 | 103,516 (0%) | 0% | 7.5 | 37,600 | Common Stock |
| William B. Bonello | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 5,000 | 5,727 | - | - | Stock Option (Right to Buy) | |
| William B. Bonello | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.29 per share. | 07 Mar 2022 | 3,209 | 98,516 (0%) | 0% | 18.3 | 58,693 | Common Stock |
| George A. Cardoza | President & COO, Lab Ops | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 503 | 244,996 (0%) | 0% | 0 | Common Stock | |
| George A. Cardoza | President & COO, Lab Ops | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 839 | 244,157 (0%) | 0% | 0 | Common Stock | |
| Halley E. Gilbert | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 42,036 | 147,396 (0%) | 0% | 0 | Common Stock | |
| Halley E. Gilbert | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 102,623 | 102,623 | - | - | Stock Option (Right to Buy) | |
| Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 347,777 | 347,777 | - | - | Stock Option (Right to Buy) | |
| Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 142,457 | 368,051 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 620 | 101,725 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 397 | 102,345 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 40,869 | 102,742 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 99,772 | 99,772 | - | - | Stock Option (Right to Buy) | |
| Douglas M. Brown | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 85,519 | 85,519 | - | - | Stock Option (Right to Buy) | |
| Douglas M. Brown | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 867 | 76,379 (0%) | 0% | 0 | Common Stock | |
| Douglas M. Brown | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 35,030 | 77,246 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 22,805 | 22,805 | - | - | Stock Option (Right to Buy) | |
| Cynthia J. Dieter | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 137 | 18,637 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 9,341 | 18,774 (0%) | 0% | 0 | Common Stock | |
| Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,677 | 33,443 (0%) | 0% | 0 | Common Stock | |
| Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 28,506 | 28,506 | - | - | Stock Option (Right to Buy) | |
| Kathryn B. McKenzie | Chief Sustainability/Risk Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 2,100 | 17,900 | - | - | Stock Option (Right to Buy) | |
| Kathryn B. McKenzie | Chief Sustainability/Risk Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.07 per share. | 11 Jan 2022 | 2,100 | 49,361 (0%) | 0% | 9.1 | 19,047 | Common Stock |
| George A. Cardoza | President & COO, Lab Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 61,143 | 245,499 (0%) | 0% | 0 | Common Stock | |
| Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 152,858 | 225,594 (0%) | 0% | 0 | Common Stock | |
| Jennifer Balliet | VP and Chief Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 21,400 | 48,615 (0%) | 0% | 0 | Common Stock | |
| Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 30,572 | 47,261 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | President, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 21,400 | 61,873 (0%) | 0% | 0 | Common Stock | |
| Douglas M. Brown | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 30,572 | 42,216 (0%) | 0% | 0 | Common Stock | |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 7,643 | 9,433 (0%) | 0% | 0 | Common Stock | |
| Clive Morris | President of Inivata | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 30,572 | 41,280 (0%) | 0% | 0 | Common Stock | |
| Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 15,286 | 21,299 (0%) | 0% | 0 | Common Stock | |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 3,334 | 0 | - | - | Stock Options (Right to Buy) | |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 22 Dec 2021 | 3,334 | 37,398 (0%) | 0% | 7.3 | 24,238 | Common Stock |
| Kathryn B. McKenzie | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 21 Dec 2021 | 1,846 | 11,689 (0%) | 0% | 35 | 64,610 | Common Stock |
| Kathryn B. McKenzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 5,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Kathryn B. McKenzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.07 per share. | 21 Dec 2021 | 5,000 | 16,689 (0%) | 0% | 9.1 | 45,350 | Common Stock |
| Mark Mallon | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 30.63 per share. | 06 Dec 2021 | 17,000 | 72,736 (0%) | 0% | 30.6 | 520,710 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 30 Nov 2021 | 25,000 | 40,473 (0%) | 0% | 7.5 | 188,000 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 25,000 | 10,727 | - | - | Stock Option (Right to Buy) | |
| William B. Bonello | President, Informatics | Sale of securities on an exchange or to another person at price $ 37.13 per share. | 24 Nov 2021 | 25,000 | 15,473 (0%) | 0% | 37.1 | 928,250 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2021 | 25,000 | 45,370 | - | - | Stock Option (Right to Buy) | |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 24 Nov 2021 | 25,000 | 40,473 (0%) | 0% | 8.0 | 200,750 | Common Stock |
| Douglas M. Brown | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 36.84 per share. | 23 Nov 2021 | 33,333 | 44,978 (0%) | 0% | 36.8 | 1,227,988 | Common Stock |
| Douglas M. Brown | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 36.85 per share. | 23 Nov 2021 | 33,334 | 11,644 (0%) | 0% | 36.9 | 1,228,358 | Common Stock |
| Douglas M. Brown | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 37.19 per share. | 23 Nov 2021 | 33,333 | 78,311 (0%) | 0% | 37.2 | 1,239,654 | Common Stock |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2021 | 972 | 972 | - | - | Stock Option (Right to Buy) | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2021 | 838 | 35,777 (0%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.10 per share. | 01 Aug 2021 | 5,919 | 2,468,797 (2%) | 0% | 46.1 | 272,866 | Common Stock |
| George A. Cardoza | President & COO, Lab Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 7,584 | 184,356 (0%) | 0% | 0 | Common Stock | |
| George A. Cardoza | President & COO, Lab Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 40,502 | 40,502 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 4,050 | 4,050 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 758 | 27,215 (0%) | 0% | 0 | Common Stock | |
| Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 1,896 | 6,013 (0%) | 0% | 0 | Common Stock | |
| Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 10,126 | 10,126 | - | - | Stock Option (Right to Buy) | |
| Cynthia J. Dieter | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.98 per share. | 22 Jun 2021 | 56 | 1,790 (0%) | 0% | 44.0 | 2,463 | Common Stock |
| Clive Morris | President of Inivata | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 53,857 | 53,857 | - | - | Stock Option (Right to Buy) | |
| Clive Morris | President of Inivata | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 10,708 | 10,708 (0%) | 0% | 0 | Common Stock | |
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2021 | 1,389 | 0 | - | - | Stock Option (Right to Buy) | |
| Lynn A. Tetrault | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.11 per share. | 11 Jun 2021 | 1,389 | 34,939 (0%) | 0% | 9.1 | 12,654 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce K. Crowther | Director | Sale of securities on an exchange or to another person at price $ 41.46 per share. | 08 Jun 2021 | 20,734 | 49,564 (0%) | 0% | 41.5 | 859,632 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.54 per share. | 08 Jun 2021 | 3,448 | 70,298 (0%) | 0% | 28.5 | 98,406 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.52 per share. | 08 Jun 2021 | 4,269 | 66,850 (0%) | 0% | 22.5 | 96,138 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.60 per share. | 08 Jun 2021 | 3,017 | 62,581 (0%) | 0% | 11.6 | 34,997 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 08 Jun 2021 | 10,000 | 59,564 (0%) | 0% | 7.3 | 72,700 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 3,448 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 4,269 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 3,017 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.33 per share. | 25 May 2021 | 14,067 | 280,705 (0%) | 0% | 28.3 | 398,518 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 14,067 | 42,204 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 16,724 | 33,449 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 96,167 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Sale of securities on an exchange or to another person at price $ 39.31 per share. | 25 May 2021 | 130,604 | 150,101 (0%) | 0% | 39.3 | 5,134,043 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.60 per share. | 25 May 2021 | 16,724 | 266,638 (0%) | 0% | 19.6 | 327,790 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 25 May 2021 | 96,167 | 249,914 (0%) | 0% | 8.0 | 772,221 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.22 per share. | 22 Apr 2021 | 6,667 | 112,464 (0%) | 0% | 9.2 | 61,470 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2021 | 9,378 | 28,136 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2021 | 9,005 | 18,012 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2021 | 6,667 | 0 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.33 per share. | 22 Apr 2021 | 9,378 | 130,847 (0%) | 0% | 28.3 | 265,679 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.60 per share. | 22 Apr 2021 | 9,005 | 121,469 (0%) | 0% | 19.6 | 176,498 | Common Stock |
| Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 151,016 | 151,016 | - | - | Stock Option (Right to Buy) | |
| Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 55,736 | 55,736 (0%) | 0% | 0 | Common Stock | |
| George A. Cardoza | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 6,207 | 377,109 (0%) | 0% | 0 | Common Stock | |
| George A. Cardoza | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 35,171 | 35,171 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 29,895 | 29,895 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 5,276 | 105,797 (0%) | 0% | 0 | Common Stock | |
| Douglas M. Brown | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 4,655 | 111,644 (0%) | 0% | 0 | Common Stock | |
| Douglas M. Brown | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 26,378 | 26,378 | - | - | Stock Option (Right to Buy) | |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,034 | 7,034 | - | - | Stock Option (Right to Buy) | |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 1,241 | 1,846 (0%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 2,158 | 2,418,293 (2%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 2,339 | 2,420,451 (2%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 56,423 | 2,474,716 (2%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 6,827 | 153,747 (0%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 608 | 146,920 (0%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 742 | 147,528 (0%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 38,688 | 38,688 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 1,862 | 26,457 (0%) | 0% | 0 | Common Stock | |
| Jennifer Balliet | VP and Chief Culture Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 173 | 24,595 (0%) | 0% | 0 | Common Stock | |
| Jennifer Balliet | VP and Chief Culture Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 212 | 24,768 (0%) | 0% | 0 | Common Stock | |
| Jennifer Balliet | VP and Chief Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 10,551 | 10,551 | - | - | Stock Option (Right to Buy) | |
| Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 35,171 | 35,171 | - | - | Stock Option (Right to Buy) | |
| Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 6,207 | 13,535 (0%) | 0% | 0 | Common Stock | |
| Kathryn B. McKenzie | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 432 | 7,328 (0%) | 0% | 0 | Common Stock | |
| Kathryn B. McKenzie | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 169 | 7,760 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | President, Informatics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 500 | 11,560 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | President, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 4,345 | 15,473 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | President, Informatics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 432 | 11,128 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | President, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 24,619 | 24,619 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 07 Jan 2021 | 10,000 | 82,932 (0%) | 0% | 7.3 | 72,700 | Common Stock |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2021 | 4,269 | 0 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2021 | 3,017 | 0 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2021 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2021 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.52 per share. | 07 Jan 2021 | 4,269 | 90,218 (0%) | 0% | 22.5 | 96,138 | Common Stock |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 07 Jan 2021 | 100,000 | 1,100,000 (1%) | 0% | 7.2 | 715,000 | Common Stock |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.60 per share. | 07 Jan 2021 | 3,017 | 85,949 (0%) | 0% | 11.6 | 34,997 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 13,333 | 6,667 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 51.06 per share. | 14 Dec 2020 | 20,200 | 100,521 (0%) | 0% | 51.1 | 1,031,412 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.60 per share. | 14 Dec 2020 | 9,005 | 120,721 (0%) | 0% | 19.6 | 176,498 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 14 Dec 2020 | 16,666 | 111,716 (0%) | 0% | 13.9 | 231,157 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.22 per share. | 14 Dec 2020 | 13,333 | 95,050 (0%) | 0% | 9.2 | 122,930 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 14 Dec 2020 | 20,000 | 81,717 (0%) | 0% | 7.3 | 145,400 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 14 Dec 2020 | 50,000 | 61,717 (0%) | 0% | 7.0 | 349,000 | Common Stock |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 9,005 | 27,017 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Weiss | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 16,666 | 8,334 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 11 Dec 2020 | 15,000 | 39,980 (0%) | 0% | 8.0 | 120,450 | Common Stock |
| Jennifer Balliet | VP and Chief Culture Officer | Sale of securities on an exchange or to another person at price $ 49.99 per share. | 11 Dec 2020 | 15,000 | 24,980 (0%) | 0% | 50.0 | 749,850 | Common Stock |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2020 | 15,000 | 33,334 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 51.67 per share. | 10 Dec 2020 | 25,000 | 1,000,000 (0%) | 0% | 51.7 | 1,291,750 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 50.52 per share. | 10 Dec 2020 | 25,000 | 1,025,000 (0%) | 0% | 50.5 | 1,263,000 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 50.30 per share. | 10 Dec 2020 | 20,000 | 1,050,000 (1%) | 0% | 50.3 | 1,006,000 | Common Stock |
| Kevin Johnson | Director | Sale of securities on an exchange or to another person at price $ 47.88 per share. | 04 Dec 2020 | 24,683 | 30,983 (0%) | 0% | 47.9 | 1,181,822 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 48.03 per share. | 03 Dec 2020 | 19,948 | 1,180,052 (1%) | 0% | 48.0 | 958,102 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 49.45 per share. | 03 Dec 2020 | 45,658 | 1,070,000 (1%) | 0% | 49.4 | 2,257,788 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 48.07 per share. | 03 Dec 2020 | 64,394 | 1,115,658 (1%) | 0% | 48.1 | 3,095,420 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 8,000 | 70,370 | - | - | Stock Option (Right to Buy) | |
| William B. Bonello | President, Informatics | Sale of securities on an exchange or to another person at price $ 46.80 per share. | 02 Dec 2020 | 8,000 | 12,060 (0%) | 0% | 46.8 | 374,400 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 02 Dec 2020 | 8,000 | 20,060 (0%) | 0% | 8.0 | 64,240 | Common Stock |
| George Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 45.48 per share. | 24 Nov 2020 | 77,074 | 370,902 (0%) | 0% | 45.5 | 3,505,326 | Common Stock |
| George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 24 Nov 2020 | 77,074 | 447,976 (0%) | 0% | 7.5 | 579,596 | Common Stock |
| George Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 45.19 per share. | 24 Nov 2020 | 52,926 | 370,902 (0%) | 0% | 45.2 | 2,391,726 | Common Stock |
| George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 24 Nov 2020 | 72,926 | 423,828 (0%) | 0% | 7.5 | 548,404 | Common Stock |
| George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2020 | 77,074 | 50,000 | - | - | Stock Option (Right to Buy) | |
| George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2020 | 72,926 | 127,074 | - | - | Stock Option (Right to Buy) | |
| Raymond R. Hipp | Director | Sale of securities on an exchange or to another person at price $ 42.28 per share. | 16 Nov 2020 | 70,000 | 66,800 (0%) | 0% | 42.3 | 2,959,600 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Douglas M. VanOort | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 358,752 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Douglas M. VanOort | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 121,248 | 378,752 | - | - | Stock Option (Right to Buy) | |
| Douglas M. VanOort | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 42.34 per share. | 12 Nov 2020 | 100,000 | 2,422,790 (2%) | 0% | 42.3 | 4,234,000 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 12 Nov 2020 | 20,000 | 2,522,790 (2%) | 0% | 7.5 | 150,400 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 41.56 per share. | 12 Nov 2020 | 118,752 | 2,502,790 (2%) | 0% | 41.6 | 4,935,333 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 12 Nov 2020 | 358,752 | 2,621,542 (2%) | 0% | 7.5 | 2,697,815 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 42.18 per share. | 12 Nov 2020 | 121,248 | 2,262,790 (2%) | 0% | 42.2 | 5,114,241 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 12 Nov 2020 | 121,248 | 2,384,038 (2%) | 0% | 7.5 | 911,785 | Common Stock |
| Steven C. Jones | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Sep 2020 | 25,000 | 72,932 (0%) | 0% | 0 | Common Stock | |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 36.55 per share. | 28 Sep 2020 | 81,000 | 97,932 (0%) | 0% | 36.6 | 2,960,550 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 36.56 per share. | 28 Sep 2020 | 19,000 | 178,932 (0%) | 0% | 36.6 | 694,640 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 36.95 per share. | 28 Sep 2020 | 141,049 | 1,200,000 (1%) | 0% | 37.0 | 5,211,761 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 36.34 per share. | 28 Sep 2020 | 38,951 | 1,341,049 (1%) | 0% | 36.3 | 1,415,479 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.11 per share. | 22 Sep 2020 | 8,333 | 54,816 (0%) | 0% | 9.1 | 75,914 | Common Stock |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Sep 2020 | 8,333 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce K. Crowther | Director | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 22 Sep 2020 | 8,333 | 46,483 (0%) | 0% | 35.0 | 291,738 | Common Stock |
| Bruce K. Crowther | Director | Sale of securities on an exchange or to another person at price $ 35.68 per share. | 22 Sep 2020 | 2,400 | 46,483 (0%) | 0% | 35.7 | 85,632 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 36.13 per share. | 08 Sep 2020 | 10,426 | 1,489,574 (1%) | 0% | 36.1 | 376,691 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 37.13 per share. | 08 Sep 2020 | 37,991 | 1,380,000 (1%) | 0% | 37.1 | 1,410,606 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 36.98 per share. | 08 Sep 2020 | 71,583 | 1,417,991 (1%) | 0% | 37.0 | 2,647,139 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Aug 2020 | 5,000 | 2,272,790 (2%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Aug 2020 | 10,000 | 2,262,790 (2%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Aug 2020 | 5,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Aug 2020 | 10,000 | 2,277,790 (2%) | 0% | 0 | Common Stock | |
| George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 06 Aug 2020 | 100,000 | 433,402 (0%) | 0% | 7.2 | 715,000 | Common Stock |
| George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| George Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 39.35 per share. | 06 Aug 2020 | 82,500 | 350,902 (0%) | 0% | 39.4 | 3,246,375 | Common Stock |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 06 Aug 2020 | 10,000 | 88,796 (0%) | 0% | 7.3 | 72,700 | Common Stock |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 13,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 03 Aug 2020 | 13,000 | 37,980 (0%) | 0% | 7.5 | 97,760 | Common Stock |
| Jennifer Balliet | VP and Chief Culture Officer | Sale of securities on an exchange or to another person at price $ 39.25 per share. | 03 Aug 2020 | 13,000 | 24,980 (0%) | 0% | 39.3 | 510,250 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 20,036 | 35,727 | - | - | Stock Option (Right to Buy) | |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 03 Aug 2020 | 20,036 | 32,096 (0%) | 0% | 7.5 | 150,671 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 03 Aug 2020 | 1,964 | 34,060 (0%) | 0% | 8.0 | 15,771 | Common Stock |
| William B. Bonello | President, Informatics | Sale of securities on an exchange or to another person at price $ 38.61 per share. | 03 Aug 2020 | 22,000 | 12,060 (0%) | 0% | 38.6 | 849,420 | Common Stock |
| William B. Bonello | President, Informatics | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 1,964 | 78,370 | - | - | Stock Option (Right to Buy) | |
| Douglas M. VanOort | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Aug 2020 | 5,953 | 2,287,790 (2%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2020 | 2,223 | 2,223 | - | - | Stock Option (Right to Buy) | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2020 | 1,782 | 1,782 (0%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2020 | 16,724 | 50,173 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2020 | 66,667 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Sale of securities on an exchange or to another person at price $ 38.17 per share. | 30 Jul 2020 | 81,356 | 148,270 (0%) | 0% | 38.2 | 3,105,359 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.60 per share. | 30 Jul 2020 | 16,724 | 229,626 (0%) | 0% | 19.6 | 327,790 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 30 Jul 2020 | 66,667 | 212,902 (0%) | 0% | 7.5 | 501,336 | Common Stock |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 3,968 | 3,968 | - | - | Stock Option (Right to Buy) | |
| Cynthia J. Dieter | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 605 | 605 (0%) | 0% | 0 | Common Stock | |
| Bruce K. Crowther | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Bruce K. Crowther | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 48,883 (0%) | 0% | 0 | Common Stock | |
| Raymond R. Hipp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 136,800 (0%) | 0% | 0 | Common Stock | |
| Raymond R. Hipp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 44,351 (0%) | 0% | 0 | Common Stock | |
| Steven C. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Steven C. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 197,932 (0%) | 0% | 0 | Common Stock | |
| Kevin Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Kevin Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 55,666 (0%) | 0% | 0 | Common Stock | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 78,796 (0%) | 0% | 0 | Common Stock | |
| Stephen Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 6,117 (0%) | 0% | 0 | Common Stock | |
| Stephen Kanovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Options (Right to Buy) | |
| Rachel A. Stahler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,448 | 3,448 | - | - | Stock Option (Right to Buy) | |
| Rachel A. Stahler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,698 | 2,698 (0%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 25 May 2020 | 22,330 | 2,293,743 (2%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 25 May 2020 | 5,405 | 146,235 (0%) | 0% | 0 | Common Stock | |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2020 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce K. Crowther | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.78 per share. | 01 May 2020 | 10,000 | 46,185 (0%) | 0% | 4.8 | 47,800 | Common Stock |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.78 per share. | 13 Mar 2020 | 125,000 | 1,500,000 (1%) | 0% | 4.8 | 597,500 | Common Stock |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2020 | 125,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Sale of securities on an exchange or to another person at price $ 30.86 per share. | 04 Mar 2020 | 98,093 | 151,640 (0%) | 0% | 30.9 | 3,027,150 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2020 | 96,167 | 96,167 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 04 Mar 2020 | 96,167 | 249,733 (0%) | 0% | 8.0 | 772,221 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 28.48 per share. | 02 Mar 2020 | 25,000 | 125,000 (0%) | 0% | 28.5 | 712,000 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 28.24 per share. | 02 Mar 2020 | 20,000 | 30,476 (0%) | 0% | 28.2 | 564,800 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 28.24 per share. | 02 Mar 2020 | 2,300 | 40,757 (0%) | 0% | 28.2 | 64,952 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 28.85 per share. | 02 Mar 2020 | 250,000 | 1,375,000 (1%) | 0% | 28.9 | 7,212,500 | Common Stock |
| George Cardoza | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2020 | 7,571 | 333,402 (0%) | 0% | 0 | Common Stock | |
| George Cardoza | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2020 | 48,768 | 48,768 | - | - | Common Stock | |
| Lawrence M. Weiss | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2020 | 37,514 | 37,514 | - | - | Common Stock | |
| Lawrence M. Weiss | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2020 | 5,824 | 11,717 (0%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 225,084 | 225,084 | - | - | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2020 | 2,353 | 2,281,128 (2%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 34,945 | 2,316,073 (2%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2020 | 810 | 144,830 (0%) | 0% | 0 | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 56,271 | 56,271 | - | - | Common Stock | |
| Robert J. Shovlin | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 8,736 | 153,566 (0%) | 0% | 0 | Common Stock | |
| Jennifer Balliet | VP and Chief Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 2,330 | 24,980 (0%) | 0% | 0 | Common Stock | |
| Jennifer Balliet | VP and Chief Culture Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2020 | 212 | 22,650 (0%) | 0% | 0 | Common Stock | |
| Jennifer Balliet | VP and Chief Culture Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 15,006 | 15,006 | - | - | Common Stock | |
| Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 5,824 | 7,929 (0%) | 0% | 0 | Common Stock | |
| Kathryn B. McKenzie | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2020 | 168 | 2,105 (0%) | 0% | 0 | Common Stock | |
| Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 37,514 | 37,514 | - | - | Common Stock | |
| William B. Bonello | President, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 5,824 | 12,060 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | President, Informatics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2020 | 499 | 6,236 (0%) | 0% | 0 | Common Stock | |
| William B. Bonello | President, Informatics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2020 | 37,514 | 37,514 | - | - | Common Stock | |
| Steven C. Jones | Director | Other type of transaction at price $ 0.00 per share. | 30 Dec 2019 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Other type of transaction at price $ 0.00 per share. | 30 Dec 2019 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2019 | 100,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Other type of transaction at price $ 0.00 per share. | 30 Dec 2019 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Other type of transaction at price $ 0.00 per share. | 30 Dec 2019 | 225,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Steven C. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.78 per share. | 30 Dec 2019 | 100,000 | 1,625,000 (1%) | 0% | 4.8 | 478,000 | Common Stock |
| Kathryn B. McKenzie | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 10 Dec 2019 | 8,000 | 10,273 (0%) | 0% | 8.0 | 64,240 | Common Stock |
| Kathryn B. McKenzie | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2019 | 8,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Kathryn B. McKenzie | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.37 per share. | 10 Dec 2019 | 8,000 | 2,273 (0%) | 0% | 26.4 | 210,960 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 24.08 per share. | 19 Nov 2019 | 187,500 | 0 (0%) | 0% | 24.1 | 4,515,000 | Common Stock |
| Jennifer Balliet | VP and Chief Culture Officer | Sale of securities on an exchange or to another person at price $ 23.45 per share. | 15 Nov 2019 | 6,833 | 22,862 (0%) | 0% | 23.5 | 160,234 | Common Stock |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2019 | 166 | 48,334 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2019 | 6,667 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 15 Nov 2019 | 166 | 29,695 (0%) | 0% | 8.0 | 1,333 | Common Stock |
| Jennifer Balliet | VP and Chief Culture Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 15 Nov 2019 | 6,667 | 29,529 (0%) | 0% | 7.5 | 50,136 | Common Stock |
| George A. Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2019 | 44,444 | 100,000 | - | - | Stock Option (Right to Buy) | |
| George A. Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 23.15 per share. | 12 Nov 2019 | 19,444 | 325,831 (0%) | 0% | 23.2 | 450,129 | Common Stock |
| George A. Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 12 Nov 2019 | 44,444 | 345,275 (0%) | 0% | 7.2 | 317,775 | Common Stock |
| George A. Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 06 Nov 2019 | 55,556 | 356,387 (0%) | 0% | 7.1 | 397,225 | Common Stock |
| George A. Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 22.82 per share. | 06 Nov 2019 | 51,556 | 304,831 (0%) | 0% | 22.8 | 1,176,508 | Common Stock |
| George A. Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 22.80 per share. | 06 Nov 2019 | 4,000 | 300,831 (0%) | 0% | 22.8 | 91,200 | Common Stock |
| George A. Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2019 | 55,556 | 144,444 | - | - | Stock Option (Right to Buy) | |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2019 | 8,333 | 0 | - | - | Stock Option (Right to Buy) | |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.78 per share. | 31 Oct 2019 | 6,667 | 34,952 (0%) | 0% | 4.8 | 31,868 | Common Stock |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.11 per share. | 31 Oct 2019 | 8,333 | 43,285 (0%) | 0% | 9.1 | 75,914 | Common Stock |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 31 Oct 2019 | 6,666 | 49,951 (0%) | 0% | 7.3 | 48,462 | Common Stock |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2019 | 3,017 | 0 | - | - | Stock Option (Right to Buy) | |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2019 | 6,666 | 3,334 | - | - | Stock Option (Right to Buy) | |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.60 per share. | 31 Oct 2019 | 3,017 | 52,968 (0%) | 0% | 11.6 | 34,997 | Common Stock |
| Kevin Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2019 | 6,667 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 31 Oct 2019 | 96,166 | 251,914 (0%) | 0% | 8.0 | 772,213 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2019 | 96,166 | 192,334 | - | - | Stock Option (Right to Buy) | |
| Robert J. Shovlin | President, Clinical Services | Sale of securities on an exchange or to another person at price $ 22.74 per share. | 31 Oct 2019 | 35,801 | 145,640 (0%) | 0% | 22.7 | 814,115 | Common Stock |
| Robert J. Shovlin | President, Clinical Services | Sale of securities on an exchange or to another person at price $ 23.11 per share. | 31 Oct 2019 | 70,473 | 181,441 (0%) | 0% | 23.1 | 1,628,631 | Common Stock |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2019 | 3,333 | 0 | - | - | Stock Option (Right to Buy) | |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2019 | 8,333 | 0 | - | - | Stock Option (Right to Buy) | |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.11 per share. | 09 Sep 2019 | 8,333 | 76,098 (0%) | 0% | 9.1 | 75,914 | Common Stock |
| Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.66 per share. | 09 Sep 2019 | 3,333 | 67,765 (0%) | 0% | 6.7 | 22,198 | Common Stock |
| Steven C. Jones | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Sep 2019 | 3,400 | 43,057 (0%) | 0% | 0 | Common Stock | |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 21.47 per share. | 06 Sep 2019 | 1,200 | 46,457 (0%) | 0% | 21.5 | 25,764 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 06 Sep 2019 | 3 | 1,676,230 (1%) | 0% | 25 | 75 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 06 Sep 2019 | 1,691 | 1,676,233 (1%) | 0% | 25 | 42,275 | Common Stock |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2019 | 30,000 | 2,036,589 (1%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2019 | 10,000 | 2,026,589 (1%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2019 | 10,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Douglas M. VanOort | Director, Chairman and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2019 | 10,000 | 2,016,589 (1%) | 0% | 0 | Common Stock | |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 28 Aug 2019 | 1,200 | 1,677,924 (1%) | 0% | 25 | 30,000 | Common Stock |
| Steven C. Jones | Director | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 28 Aug 2019 | 39,537 | 1,679,124 (1%) | 0% | 25.0 | 989,216 | Common Stock |
| William B. Bonello | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 28 Aug 2019 | 17,000 | 23,735 (0%) | 0% | 7.5 | 127,840 | Common Stock |
| William B. Bonello | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 24.83 per share. | 28 Aug 2019 | 17,000 | 6,735 (0%) | 0% | 24.8 | 422,110 | Common Stock |
| William B. Bonello | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2019 | 17,000 | 55,763 | - | - | Stock Option (Right to Buy) | |
| Raymond R. Hipp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.60 per share. | 23 Aug 2019 | 3,017 | 144,016 (0%) | 0% | 11.6 | 34,997 | Common Stock |
| Raymond R. Hipp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 23 Aug 2019 | 3,333 | 147,349 (0%) | 0% | 7.3 | 24,231 | Common Stock |
| Raymond R. Hipp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.11 per share. | 23 Aug 2019 | 2,777 | 150,126 (0%) | 0% | 9.1 | 25,298 | Common Stock |
| Raymond R. Hipp | Director | Sale of securities on an exchange or to another person at price $ 24.79 per share. | 23 Aug 2019 | 15,424 | 134,102 (0%) | 0% | 24.8 | 382,361 | Common Stock |
| Raymond R. Hipp | Director | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 23 Aug 2019 | 600 | 149,526 (0%) | 0% | 25.0 | 15,012 | Common Stock |
| Raymond R. Hipp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2019 | 2,777 | 0 | - | - | Stock Option (Right to Buy) |